



July 9th, 2020

Office of the Vermont Attorney General
109 State Street
Montpelier, VT 05609

Re: New High-Cost Prescription Drugs Reporting

Dear Office of the Vermont Attorney General,

In compliance with 18 V.S.A. § 4637, Amneal Pharmaceuticals LLC ("Amneal") has introduced new generic prescription drugs ("Products") at a wholesale acquisition cost that is over the threshold set for a specialty drug under the Medicare Part D program, which is attached as Exhibit A. This letter also provides the additional required information by 18 V.S.A. § 4637(c) regarding the Product. Amneal notes that the Office of the Attorney General has not yet prescribed a format for submissions under this section. Further, as authorized by 18 V.S.A. § 4637(d), Amneal has limited the information reported to that which is in the public domain or publicly available.

- (1) A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally;

This drug is a generic product; therefore no marketing and pricing plans are available. This Product is sold in the United States only.

- (2) The estimated volume of patients who may be prescribed the drug;

The estimated average number of patients per month is unknown to Amneal.

- (3) Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval;

Not applicable.

- (4) The date and price of acquisition if the drug was not developed by the manufacturer;

Amneal did not acquire this product.

Regards,

A handwritten signature in blue ink that reads "Leslie Restaino".

Leslie Restaino
VP, Chief Compliance Officer

EXHIBIT A

NDC	PRODUCT	DATE OF INTRO TO MARKET	WAC
60219-1680-01	Fluphenazine HCl 5 mg	7/9/2020	689.95
60219-1681-01	Fluphenazine HCl 10 mg	7/9/2020	869.90